Compare MEG & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEG | MGTX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | 3500 | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 930.8M | 909.1M |
| IPO Year | 2020 | 2018 |
| Metric | MEG | MGTX |
|---|---|---|
| Price | $22.14 | $9.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $35.25 | $24.57 |
| AVG Volume (30 Days) | 266.4K | ★ 715.9K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.69 | 33.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $830,538,000.00 | $81,391,000.00 |
| Revenue This Year | $5.41 | $141.38 |
| Revenue Next Year | $7.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 19.26 | ★ 144.57 |
| 52 Week Low | $20.10 | $6.21 |
| 52 Week High | $32.00 | $11.85 |
| Indicator | MEG | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.09 | 43.91 |
| Support Level | $20.80 | $8.82 |
| Resistance Level | $23.48 | $9.65 |
| Average True Range (ATR) | 0.79 | 0.50 |
| MACD | 0.13 | -0.10 |
| Stochastic Oscillator | 88.92 | 5.54 |
Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits and permits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, and soil remediation. The company derives maximum revenue from United States.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.